What a Paragraph IV certification means for a generic drug
A Paragraph IV certification says a listed patent is invalid, unenforceable or not infringed. How notice, the 30-month stay and 180-day exclusivity work.
A Paragraph IV certification is a statement in a US generic drug application (an ANDA). The applicant certifies that a patent listed for the brand drug is invalid, unenforceable, or will not be infringed by the proposed generic. It lets a generic company seek FDA approval before that patent expires, but it is the applicant's own claim: it is not FDA approval, a court ruling or an automatic right to 180-day exclusivity.
The rules sit in 21 CFR 314.94 (what the ANDA must certify), 21 CFR 314.95 (notice to the patent owner) and 21 CFR 314.107 (when FDA can approve). This is the Hatch-Waxman framework of US law. UK readers should treat it as the route into the US market only, because it is not part of how UK medicines are authorised.
The four patent certifications
For each relevant listed patent, the ANDA must identify the patent and make one of four certifications under section 314.94(a)(12). FDA summarises the same options on its patent certifications page.
| Certification | What the applicant certifies |
|---|---|
| Paragraph I | The required patent information has not been submitted to FDA |
| Paragraph II | The patent has expired |
| Paragraph III | The date on which the patent will expire |
| Paragraph IV | The patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the proposed drug |
Paragraph I does not mean that no patents exist. The regulation deals with the case of no relevant patents separately. A Paragraph III certification means that the patent's expiry is a condition for approval, not a guarantee of approval then. A Paragraph IV certification must carry the title "Paragraph IV Certification".
A section viii statement is something else. For a method-of-use patent that does not claim the indication or other condition of use the applicant wants, the ANDA can say so and omit the related labeling, within the limits in sections 314.94(a)(12)(iii) and (a)(8)(iv). It is not a fifth certification and does not let an applicant carve out any patented use it likes.
Notice to the patent owner and NDA holder
Filing the certification with FDA is not enough. Under section 314.95, the applicant must send notice to each patent owner (or its designated representative) and to the holder of the approved NDA. The notice must give a detailed statement of the factual and legal basis for the applicant's view that the patent is invalid, unenforceable or not infringed.
Timing depends on when the certification is made:
- For an original ANDA, notice goes out on or after the day the applicant receives FDA's Paragraph IV acknowledgment letter, and no later than 20 days after that letter's postmark. Receipt sets the earliest send date. The postmark sets the deadline.
- For a new Paragraph IV certification made after acknowledgment, in an amendment or supplement, notice is sent when that amendment or supplement is submitted (section 314.95(d)).
The rule has further qualifications on how the clock runs and when a notice is invalid. Work out a real deadline from the regulation text and the acknowledgment letter, not from a summary.
The 45-day window and the 30-month stay
Receipt of notice starts a 45-day window. If qualifying infringement litigation is filed within 45 days of receipt of notice, and the patent information was submitted before the original application, final approval is generally held back. That is the 30-month stay in section 314.107(b)(3).
Three limits follow from that section:
- The 30 months run from the later date of receipt of notice by the patent owner(s) or the NDA holder. They do not run from the day the lawsuit is filed, and they do not run from the ANDA filing date.
- The 45 days decide whether the stay applies. They are not a limitation period after which the patent owner can never sue.
- The stay is a bar on final approval, not on FDA review. FDA can keep reviewing the application, and where approval barriers remain, section 314.107 deals with tentative approval. A tentative approval does not permit marketing.
A court can shorten or extend the 30 months if either party fails to cooperate reasonably in expediting the case. The period can also end early. Specified court decisions in the applicant's favor, consent, court orders terminating the stay and qualifying dismissals can each permit approval before 30 months, as set out in section 314.107(b).
Not every patent case triggers a stay. Section 314.107(b)(2) says the 45-day period does not apply to certain patents submitted after the original application. Where the brand drug has five-year new chemical entity exclusivity, a separate provision can measure approval timing from a point 7.5 years after the brand NDA was approved. That is a specific scenario, not a general 7.5-year stay.
When the 30 months end, approval is still not automatic. Other listed patents, other exclusivities, injunctions and the ordinary scientific and regulatory requirements for approval can all still stand in the way. The end of a stay also says nothing about the generic company's exposure to patent damages.
180-day exclusivity for the first applicant
FDA explains on its patent certifications page that the first company or companies to submit a substantially complete ANDA with a Paragraph IV certification may be eligible for 180-day exclusivity.
Under section 314.107(c), FDA will not approve a later Paragraph IV ANDA while a first applicant is eligible for exclusivity or within its 180-day period. The barrier applies to subsequent Paragraph IV ANDAs. It does not block every competing product.
In 21 USC 355(j)(5)(B)(iv), the 2024 official edition of the US Code states:
- "First" refers to a substantially complete application with a qualifying Paragraph IV certification submitted on the first day such applications came in, and the applicant must lawfully maintain that certification. It does not mean first to be approved.
- Several companies can be first applicants on the same day.
- The 180 days start with first commercial marketing by any first applicant, including commercial marketing of the listed drug. That shared period does not restart when another co-first applicant launches.
- Eligibility can be forfeited, for example for failure to market, withdrawal of the application or loss of the qualifying certification. The forfeiture tests have several parts and specific deadlines, so check the statute rather than relying on a rule of thumb.
FDA publishes a list of Paragraph IV certifications with eligibility and forfeiture status on its patent certifications page. FDA says its decisions rest on the application record, not the list. A blank entry proves neither eligibility nor forfeiture.
Authorized generics during exclusivity
An authorized generic is marketed under the brand's existing NDA, rather than a separate NDA or ANDA. According to FDA's list of authorized generic drugs, it is the brand drug product sold without the brand name, possibly with different color or markings. A conventional generic, by contrast, is approved through its own ANDA.
The 180-day barrier in section 314.107(c) stops FDA approving later Paragraph IV ANDAs. It does not reach a product already covered by the brand's NDA, so the brand company can launch an authorized generic during the first applicant's exclusivity period.
Paragraph IV in 505(b)(2) applications
Paragraph IV is not limited to ANDAs. Section 314.107 applies its patent-related approval timing to 505(b)(2) applications as well. A 505(b)(2) applicant can make a Paragraph IV certification, and a stay can apply when the stay conditions are met. The 180-day first-applicant exclusivity described above, though, is an ANDA mechanism under section 505(j). A 505(b)(2) NDA applicant does not earn it.
Checking a specific product
For a real filing, check the application's patent, notice, litigation and approval records against the current text of 21 CFR 314.107 and FDA's Paragraph IV list, and get patent counsel's view on freedom to launch.
You can see how RegAffairs AI answers what a Paragraph IV certification is, when a lawsuit delays approval and whether authorized generics can compete, with citations to the CFR text.